Indeed, clinical trials which analyzed the efficacy of ICI with anti-PD-1 therapy in recurrent and/or metastatic HNSCC showed that only 15–20% of patients benefit from this treatment, emphasizing the need for additional immunotherapeutic approaches, such as immunotherapeutic vaccines (45). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.